Streetbeat News

NGNE

Neurogene Inc.

https://www.neurogene.com

Industry

Biotechnology

Neurogene Inc. develops life-changing genetic medicines for patients and their families affected by neurological diseases. Its product candidate includes NGN-401, an investigational AAV9 gene therapy for the treatment of Rett syndrome; and NGN-101 to treat neuronal ceroid lipofuscinosis subtype 5 batten disease. The company is headquartered in New York, New York.

Open

20.90

Mkt cap

224M

Volume

1.2M

High

20.99

P/E Ratio

-4.71

52-wk high

74.49

Low

17.01

Div yield

N/A

52-wk low

12.49

Pomerantz LLP is investigating claims on behalf of investors of Neurogene Inc. (NASDAQ: NGNE). Investors are encouraged to contact the law firm for more information.

Portfolio Pulse from

November 19, 2024 | 12:45 am

Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of Neurogene Inc. (NASDAQ:NGNE) investors. Stockholders are encouraged to connect with the firm for more information.

Portfolio Pulse from

November 18, 2024 | 3:15 pm

Levi & Korsinsky has initiated an investigation into Neurogene Inc. (NASDAQ:NGNE) for potential securities fraud violations. This follows Neurogene's recent press release on interim clinical data from its NGN-401 gene therapy trial.

Portfolio Pulse from

November 18, 2024 | 12:45 pm

Neurogene Inc. (Nasdaq: NGNE) has provided an update on its Phase 1/2 clinical trial for NGN-401, a gene therapy for Rett syndrome. A serious adverse event (SAE) related to the treatment has emerged in a trial participant.

Portfolio Pulse from

November 18, 2024 | 12:00 pm

Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of Neurogene Inc. (NASDAQ:NGNE) investors. Stockholders are encouraged to contact the firm for more information.

Portfolio Pulse from

November 17, 2024 | 3:15 pm

Levi & Korsinsky has initiated an investigation into Neurogene Inc. (NASDAQ:NGNE) for potential violations of federal securities laws. This follows a press release by Neurogene reporting interim clinical data from a Phase 1/2 trial of NGN-401 gene therapy for Rett syndrome.

Portfolio Pulse from

November 15, 2024 | 3:30 pm

Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of Neurogene Inc. (NASDAQ:NGNE) investors. Stockholders are encouraged to learn more about the investigation.

Portfolio Pulse from

November 15, 2024 | 3:15 pm

Portfolio Pulse from

November 14, 2024 | 3:45 pm

Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of Neurogene Inc. investors. They encourage investors who purchased Neurogene securities to inquire about the investigation.

Portfolio Pulse from

November 14, 2024 | 3:15 pm

Neurogene's stock experienced a significant drop of 44% following bad news, despite having been up 269% year-to-date. The decline began in after-hours trading on Monday and continued through Tuesday.

Portfolio Pulse from

November 14, 2024 | 12:15 pm

All corporate logos and prices are for illustrative purposes only and are not a recommendation, an offer to sell, or a solicitation of an offer to buy any security.